InnoCare Pharma (09969): Enters into a Strategic Research Collaboration and License Agreement with Eli Lilly and Company to Develop New Drugs

Zhitong Finance APP News, InnoCare Pharma (09969) announced that the company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company, a leading global pharmaceutical company, to develop new drugs. Under the agreement, the company will leverage its proprietary drug development platform and extensive research experience to develop and advance compounds targeting up to five targets to address critical unmet medical needs.